Peptide News Digest

Samsung-PolyPeptide $1.8B Tender Offer, PCAC 2 Days Out, Fortune Peptide Telehealth Feature

Samsung Biologics $1.8B PolyPeptide bid; PCAC 2 days out; Mason-Dixon 52% support poll; Fortune on telehealth peptide market stakes.

7 stories · Covering industry, regulatory

Editor's Note

Tuesday delivered the biggest peptide manufacturing deal of the year and a wave of pre-vote coverage two days before the PCAC opens at White Oak. Samsung Biologics extended a 1.46 billion Swiss franc ($1.8 billion) all-cash public tender offer for Switzerland's PolyPeptide Group at CHF 44.31 per share (a 40% premium to the undisturbed price), the largest biopharmaceutical acquisition in South Korean history. The strategic thesis: peptide-based GLP-1 therapies for obesity and diabetes are driving CDMO demand that Samsung Biologics wants to serve at scale. PolyPeptide's board unanimously recommended the offer and the largest shareholder gave an irrevocable tender undertaking for approximately 55.65% of outstanding shares. On the regulatory side, the FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting is two days out; the written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, and the two-day vote opens Thursday July 23 at 8:00 AM ET. A Mason-Dixon national poll of 1,000 adults commissioned by Peppies.com and released Monday found 52% of Americans favor legal peptide compounding access through licensed US pharmacies with a doctor's prescription versus 3% opposed (a 19-to-1 ratio among those with an opinion). Fortune published Monday a feature framing the vote as a potential multibillion-dollar telehealth market opening for Hims, Ro, and other GLP-1 telehealth companies looking beyond compounded semaglutide.

Industry

Samsung Biologics Announces Sunday-Monday July 19-20 an All-Cash Public Tender Offer to Acquire Swiss Peptide CDMO PolyPeptide Group for CHF 1.46 Billion ($1.8 Billion) at CHF 44.31 Per Share (40% Premium to the Undisturbed Share Price of CHF 31.65) — The Largest Biopharmaceutical M&A in South Korean History Anchored on Rising Client Demand for Peptide-Based GLP-1 Therapies in Obesity and Diabetes; PolyPeptide Board Unanimously Recommends the Offer and the Largest Shareholder Has Given an Irrevocable Tender Undertaking for Approximately 55.65% of Outstanding Shares

Samsung Biologics announced Sunday-Monday July 19-20, 2026 an all-cash public tender offer to acquire Switzerland's PolyPeptide Group for CHF 1.46 billion ($1.8 billion) at CHF 44.31 per share, a 40% premium to the undisturbed share price of CHF 31.65. The transaction represents the largest biopharmaceutical M&A in South Korean history. Strategic rationale: PolyPeptide is a global peptide contract development and manufacturing organization (CDMO) with accelerating revenue growth driven by rising client demand for peptide-based GLP-1 therapies for obesity and diabetes. The acquisition expands Samsung Biologics' capabilities beyond monoclonal antibody manufacturing (its historical strength) into peptide therapeutics and adds PolyPeptide's global network spanning Sweden, Belgium, France, the United States, and India, encompassing R&D, development, and commercial manufacturing capabilities. PolyPeptide's Board of Directors unanimously recommends the offer. The largest shareholder has given an irrevocable tender undertaking representing approximately 55.65% of outstanding shares. Samsung Biologics expects to complete the deal by end of 2026. The deal extends the July 2026 peptide-manufacturing consolidation wave alongside Novartis's $1.5 billion Myricx Bio acquisition (ADC payloads, July 6) and Lonza's Nona Biosciences TfR1 blood-brain-barrier deal (July 2).

#samsung-biologics #polypeptide-group #cdmo #peptide-manufacturing #m-and-a #glp-1 #obesity #diabetes #tender-offer #south-korea
Regulatory

FDA Pharmacy Compounding Advisory Committee Peptide Meeting Two Days Out — Written-Comment Docket FDA-2025-N-6895 Closes at 11:59 PM ET Wednesday July 22, With the Thursday-Friday July 23-24 Vote Opening at 8:00 AM ET Thursday and Closing at 3:50 PM ET Friday at FDA White Oak Campus in Silver Spring, Maryland: Day 1 (Thursday) Reviews BPC-157, KPV, TB-500, and MOTS-c; Day 2 (Friday) Reviews Emideltide (DSIP), Semax, and Epitalon; The Washington Post Reports on July 17 That FDA Career Staff Raised Conflict-of-Interest Concerns Ahead of the New Peptide Panel

The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting is two days out. Written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026 (comments received via the Regulations.gov electronic filing system after that time will not be considered). The two-day meeting opens Thursday July 23 at 8:00 AM ET and closes Friday July 24 at 3:50 PM ET at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. The Washington Post reported on July 17 that FDA career staff had raised conflict-of-interest concerns ahead of the new panel composition, adding to the June 29 STAT News reporting that seven of eight new PCAC members named have documented ties to peptide-related businesses. FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List. The American Pharmacists Association (APhA) filed docket comments this month urging the FDA to put patient safety first in the review.

#pcac #fda #docket #bpc-157 #kpv #tb-500 #mots-c #emideltide #semax #epitalon #peptide-compounding #washington-post #apha #conflict-of-interest
Industry

Mason-Dixon National Poll of 1,000 Adults Commissioned by Peppies.com and Released Monday Ahead of the PCAC Vote Shows 52% of Americans Favor Legal Peptide Compounding Access Through a Licensed US Pharmacy With a Doctor's Prescription, 3% Are Opposed, and 45% Are Unsure — a 19-to-1 Support Ratio Among Those With an Opinion; The Same Poll Documented 60% Support for a US Healthcare System That Prioritizes Preventing Illness Versus 19% for Treating Existing Illness

A Mason-Dixon Polling & Strategy national telephone survey of 1,000 adults commissioned by peptide-education resource Peppies.com released Monday July 20, 2026 documented broad American support for legal peptide compounding access. Field dates: July 13-16, 2026. Sample drawn from a nationwide voter-registration list including landlines and mobile phones, with quotas by state to reflect the adult population. Key finding: 52% of respondents favor being able to obtain peptides through a licensed US pharmacy with a doctor's prescription, 3% oppose, and 45% are unsure. Among the 55% of adults expressing an opinion, adult access is favored by a 19-to-1 ratio. Secondary findings: 60% say the US healthcare system should prioritize preventing illness versus 19% who say it should prioritize treating existing illness, framing the peptide-access debate in the broader public-health prevention conversation. The poll landed days before the FDA Pharmacy Compounding Advisory Committee (PCAC) opens the July 23-24 vote on seven peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) at White Oak. The Peppies.com commissioning framing casts the current situation as 'peptide roulette' — patients buying gray-market products of unknown quality because licensed compounding pathways are closed.

#mason-dixon #peppies-com #national-poll #peptide-compounding #public-opinion #pcac #peptide-access #healthcare-prevention
Industry

Fortune Feature Published Monday July 20: 'The FDA's Peptide Vote Could Create Telehealth's Next Multibillion-Dollar Market' — The Story Frames the July 23-24 PCAC Vote as a Commercial Inflection Point for Hims & Hers, Ro, LifeMD, and Other GLP-1 Telehealth Platforms Looking for the Next High-Growth Category Beyond Compounded Semaglutide and Tirzepatide; Complements the Same-Day STAT News Investigation of LifeMD Alleging Volume-Over-Safety Practices in the GLP-1 Prescription Business

Fortune published Monday July 20, 2026 a feature framing the FDA Pharmacy Compounding Advisory Committee's July 23-24 peptide vote as a potential commercial inflection point for the telehealth industry. The article positions Hims & Hers (NYSE: HIMS), Ro, LifeMD (NASDAQ: LFMD), and other GLP-1 telehealth platforms as the natural commercial channels for legal peptide compounding if any of the seven peptides win 503A bulks-list eligibility. The commercial thesis: compounded GLP-1 volume has been the primary telehealth growth driver over 2024-2026, but the April 2025 FDA determination that semaglutide and tirzepatide shortages had resolved (and the April 30, 2026 proposed permanent 503B exclusion) closed the compounding channel for weight-loss demand; a favorable PCAC recommendation followed by FDA rulemaking would open a fresh compoundable-substance category (BPC-157, TB-500, KPV, MOTS-c, and others) that telehealth companies could sell into legally through licensed 503A pharmacies. The Fortune feature ran the same day as the STAT News investigation of LifeMD alleging former-employee patient-safety concerns; the two stories together frame the telehealth channel as simultaneously commercially opportunistic and clinically under scrutiny.

#fortune #hims-hers #ro #lifemd #glp-1-telehealth #peptide-compounding #pcac #commercial-inflection #peptide-telehealth
Regulatory

FDA Publishes Final PCAC Peptide Briefing Documents on or Around Tuesday July 21 (Two Business Days Before the Thursday July 23 Meeting Opens): The Career-Staff Documents Released June 29-30 and Now Formally Posted for Public Access Recommend Against Adding Any of the Seven Peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, Epitalon) to the 503A Bulks List, Citing Immunogenicity Adverse Events, Heavy-Metal and Microbial Contamination in Compounding-Channel Samples, Mislabeled Contents, and Thin 503A Historical Use

The FDA published the final Pharmacy Compounding Advisory Committee briefing documents for the July 23-24 peptide meeting on or around Tuesday July 21, 2026, matching the agency's policy of making advisory-committee briefing documents public no later than two business days before the meeting. The seven career-staff briefing documents (one per peptide: BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, Epitalon) had already been publicly released in interim form on June 29-30, 2026 and became widely covered mainstream news through the July NPR feature, the Washington Post 'peptide showdown' Health Brief, and the STAT News reporting on panel-composition conflicts. The finalized documents formally posted to the docket recommend against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity adverse events, heavy-metal and microbial contamination in samples pulled from the compounding channel, mislabeled contents, and thin 503A historical use as the specific evidence gaps that prevent bulks-list inclusion. Publication of the final briefing documents means PCAC panelists have their complete reading package and the seven substance-specific evidence maps are the record they will deliberate against during the Thursday-Friday vote.

#fda #pcac #briefing-documents #bpc-157 #kpv #tb-500 #mots-c #emideltide #semax #epitalon #career-staff #immunogenicity #contamination
Industry

General Bio Raises $7.4 Million Seed Round to Advance an Oral Peptide Delivery Platform for GLP-1 Weight-Loss Drugs and Other Peptide Therapeutics According to Monday July 20 Axios Pro Biotech Deals Exclusive Reporting; CEO David Kim Confirmed the Company Is Pursuing a Larger Follow-On Round to Scale Preclinical and Early Clinical Development Against Established Oral-Peptide Competitors Including Novo Nordisk's Wegovy Pill (Oral Semaglutide 25 mg), Merck's LIPFENDRA (Enlicitide) Oral PCSK9 Inhibitor, and MindRank AI's MDR-001 Phase 3 Chinese Oral GLP-1

General Bio, a developer of oral GLP-1s and other peptides, has raised $7.4 million and is pursuing a larger follow-on funding round, CEO David Kim told Axios Pro Biotech Deals in an exclusive report published Monday July 20, 2026. The company is one of several new-generation oral peptide startups seeking to compete against the established oral-peptide market, which now spans Novo Nordisk's Wegovy pill (oral semaglutide 25 mg, launched January 2026, over 3 million US prescriptions by June), Merck's LIPFENDRA (enlicitide, oral macrocyclic peptide PCSK9 inhibitor FDA-approved July 16, 2026), and MindRank AI's MDR-001 (AI-designed oral small-molecule GLP-1RA in Phase 3 MOBILE trial in China, $52M Series B closed July 9). The oral peptide category economics are shaped by macrocyclic peptide chemistry (Merck's LIPFENDRA approach) that allows survival through the gastrointestinal tract, permeation-enhancer formulations (Novo's SNAC technology for oral semaglutide), and next-generation delivery platforms including Rani Therapeutics' RaniPill capsule (July 9 collaboration announced with China's PegBio). Seed-stage entrants like General Bio typically position on proprietary chemistry or delivery mechanisms that could enable next-generation peptides beyond the current oral GLP-1 wave.

#general-bio #oral-peptide #glp-1 #seed-round #startup #david-kim #axios #oral-drug-delivery
Regulatory

American Pharmacists Association (APhA) Formally Submits Docket Comments to FDA-2025-N-6895 Urging the Pharmacy Compounding Advisory Committee to Prioritize Patient Safety, Scientific Evidence, and Regulatory Oversight in the July 23-24 Review of Seven Peptide Substances; Statement From APhA Vice President of Professional Affairs Brigid Groves, PharmD, MS: 'Pharmacists Believe in Innovation, But Innovation Must Be Grounded in Science and Patient Safety' — The Filing Joins Partnership for Safe Medicines, Public Citizen, and Institute for Safe Medication Practices in the Formal Public-Comment Record

The American Pharmacists Association (APhA) submitted comments to FDA docket FDA-2025-N-6895 on Thursday July 17, 2026 urging the Pharmacy Compounding Advisory Committee to prioritize patient safety, scientific evidence, and regulatory oversight when evaluating the seven peptide substances up for review July 23-24. APhA warned that current black and gray markets for peptides expose patients to significant risks including contamination, inaccurate dosing, counterfeit ingredients, and serious adverse health consequences. Brigid Groves, PharmD, MS, APhA Vice President of Professional Affairs, said in the associated statement: 'Pharmacists believe in innovation, but innovation must be grounded in science and patient safety.' APhA emphasized that compounding pharmacists have a long history of helping patients access customized and safely prepared therapies when there is a legitimate clinical need, and that if rigorous peer-reviewed research demonstrates safety and efficacy for the seven peptides under review, pharmacists will play an essential role in preparing high-quality compounded formulations. The APhA filing joins docket comments from the Partnership for Safe Medicines (opposing addition), Public Citizen (opposing addition), Institute for Safe Medication Practices (raising safety concerns), the Alliance for Pharmacy Compounding (supporting bulks-list inclusion with quality safeguards), and individual academic scientists including UC Davis's Paul Knoepfler.

#apha #american-pharmacists-association #brigid-groves #pcac #docket #peptide-compounding #patient-safety #public-comment #partnership-for-safe-medicines #public-citizen